Search
for
Sort by
Research 151–180 of 1000+
- IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA
- Strategies for Managing Suboptimal Response to JAK Inhibitors in Alopecia Areata
- Reddit Analysis Reveals Common Questions of Patients with Alopecia Areata about JAK Inhibitors for Hair Loss.
- 75360 Nasal hair (vibrissae) involvement in patients with alopecia areata universalis: preliminary results showing density modification and response to oral JAK inhibitors
- TĘTNIAK AORTY NA OSI CZASU – CZY, KIEDY I JAK LECZYĆ
- Differences in activation of β-catenin in outer root sheath cells between the type of JAK inhibitor: An alternative mechanism promoting hair growth by JAK inhibitors in alopecia areata
- The JAK/STAT signaling pathway: from bench to clinic
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Janus kinase inhibitors in dermatology: A systematic review
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
- Topical Janus kinase inhibitors: A review of applications in dermatology
- Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention
- Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses
- Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Inhibiting Janus kinases to treat alopecia areata
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata
- Pathomechanisms of immune-mediated alopecia
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- Immune cell regulation of the hair cycle
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation